Low blood sugar and Wegovy® tablets

The tablet evidence, situation by situation

Section 5.4 of the US label and the hypoglycemia part of section 6.1 mention the tablet in a few specific places. Laid side by side with the European tablet information, they look like this ^[1][2].

Where the familiar numbers come from

If you have seen a hypoglycemia percentage quoted for Wegovy®, it comes from Study 3 (STEP 2), a 68-week injection trial in adults with type 2 diabetes. There, a plasma glucose below 54 mg/dL was reported in 6.2% of people on the 2.4 mg injection and 2.5% on placebo, and one person on the injection had a severe episode that needed intravenous glucose ^[1]. The European tablet product information quotes the same STEP 2 figures and notes that the risk was higher with a sulfonylurea ^[2]. These are injection results, and neither document presents them as tablet data.

For people without diabetes, the US label says only that episodes of low blood sugar have been reported with GLP-1 medicines and that the Wegovy® weight trials did not capture them systematically. From the injection heart-outcomes trial it adds that a history of bariatric surgery is a risk factor: serious lows happened in 2 of 87 people with that history on the injection and none of 97 on placebo ^[1].

What the tablet trial itself shows

OASIS 4, the trial behind the tablet approval, enrolled adults without diabetes who had obesity, or overweight with a related condition, and gave them 25 mg tablets or placebo for 64 weeks ^[1][3]. The sponsor’s results on ClinicalTrials.gov list every non-serious event reported by at least 5% of either group, and every serious event. Hypoglycemia appears in neither list ^[4].

That is reassuring only up to a point. Because people with diabetes were excluded, and because the label says the weight trials did not look for lows systematically, the registry cannot tell you how often mild lows occurred. It mainly confirms that no serious hypoglycemia was recorded in that trial population ^[1][4].

If you have type 2 diabetes

Section 8.6 adds something specific to the pill. No study has tested Wegovy® tablets for weight loss in adults who have type 2 diabetes. In people with diabetes, average semaglutide levels after the 25 mg tablet were lower than after the 2.4 mg weekly injection, and tablet levels varied more from person to person in every group, so some people with diabetes may not reach a working level ^[1]. Europe says the same in its own words, and adds that experience is limited in type 2 diabetes with an HbA1c below 8% or with insulin, for the 25 mg tablet ^[2].

A modelling study written mostly by the manufacturer’s scientists filled part of the gap with simulation rather than patients: it estimated that the 25 mg tablet would still lower weight more than placebo in people with type 2 diabetes, though by less than in people without diabetes. Simulated trials cannot report how often real people had lows ^[5].

For an inadequate response in diabetes the US label lists options for the prescriber, including switching to the injection, and section 2.1 asks that blood glucose be checked before and during treatment in anyone with diabetes ^[1].

Insulin and sulfonylureas

The combination both documents worry about most is semaglutide plus insulin or a medicine that pushes the pancreas to release insulin, such as a sulfonylurea. Sections 5.4 and 7.1 say severe low blood sugar becomes possible and that prescribers may lower the dose of those other medicines when Wegovy® is started. The label adds that use with insulin, and use in type 1 diabetes, has not been evaluated ^[1]. The European leaflet tells readers their doctor may ask them to test blood sugar to help decide on those dose changes ^[2].

The Medication Guide calls low blood sugar in people with type 2 diabetes both a common and a potentially serious side effect, and asks you to learn with your provider how to recognise and treat it ^[1].

Why it can happen

What the label supports: semaglutide stimulates insulin release and lowers glucagon in a glucose-dependent way, which is how it brings blood sugar down. On its own that action is tied to glucose levels; the label’s concern centres on medicines such as insulin and sulfonylureas that keep pushing glucose down regardless ^[1]. The European information adds that when blood sugar is already low, semaglutide reduces insulin release and does not blunt glucagon ^[2].

What is not measured for the tablet: whether the morning routine of the pill, taken fasting with a sip of water and followed by a 30-minute wait, changes the risk of lows. Neither the US label nor the European information addresses it, so this page does not guess ^[1][2].

General background: MedlinePlus explains that low blood sugar happens when glucose is used up too fast, released too slowly or met by too much insulin, and that in people with diabetes it is linked mainly to insulin and certain other diabetes medicines ^[6].

Other causes worth knowing

In people who do not have diabetes, MedlinePlus lists drinking alcohol, some types of weight-loss surgery (usually years afterwards), severe heart, kidney or liver failure, whole-body infection, missing hormones such as cortisol, a rare insulin-making tumour and some non-diabetes medicines among causes of low blood sugar ^[6].

For people with diabetes, NIDDK adds not eating enough carbohydrate, fasting while still taking glucose-lowering medicines, more physical activity than usual, alcohol without food and being unwell ^[7]. Shaky, sweaty or dizzy moments on Wegovy® tablets can also come from dehydration after vomiting or diarrhea, which the label covers separately.

What helps, according to the sources

• Learn the signs and the treatment plan with your provider before you need them; the Medication Guide and section 17 both ask for this ^[1].
• If you take insulin or another glucose-lowering medicine, NIDDK suggests checking glucose the way your team shows you, carrying a fast-acting carbohydrate and planning around alcohol and exercise ^[7].
• NIDDK describes glucagon as the treatment for a severe low that you cannot treat yourself, and suggests teaching family or coworkers how to use it and wearing a medical alert ID ^[7].
• MedlinePlus advises not driving yourself to the emergency room if symptoms persist after a sugary snack ^[6]; Europe advises avoiding driving with any sign of a low ^[2].

Signs the Medication Guide lists

• Dizziness or light-headedness, shakiness, weakness or a jittery feeling ^[1].
• Sweating, a fast heartbeat or a headache ^[1].
• Hunger, anxiety, irritability or other changes in mood ^[1].
• Blurred vision, slurred speech, confusion or drowsiness ^[1].

One tablet a day, and a missed one stays missed

The tablet’s own rules matter here. The label says not to take more than one tablet a day, and if a dose is missed, to skip it and simply take the next one the following day. Section 10 lists severe hypoglycemia among the effects seen in overdoses of GLP-1 medicines, together with severe nausea and vomiting ^[1].

If too much is taken, the Medication Guide says to call your healthcare provider or the Poison Help line (1-800-222-1222), or to head to the nearest emergency room. Because semaglutide has a half-life of about a week, the label notes that observation may need to go on for a long time ^[1].

Wegovy® is a registered trademark of Novo Nordisk A/S. PepLabo is not affiliated with or endorsed by Novo Nordisk.